Clinical Trials Logo

Methamphetamine Abuse clinical trials

View clinical trials related to Methamphetamine Abuse.

Filter by:

NCT ID: NCT06410196 Not yet recruiting - Clinical trials for Methamphetamine Abuse

Mood and Decision-making in Methamphetamine Use Disorder

MDM-MUD
Start date: July 2024
Phase: N/A
Study type: Interventional

In this project, the investigators examine behavior and associated brain activity during explore-exploit decision-making tasks performed pre- and post-modulation of affective state using autobiographical memory recall. The investigators hypothesize that a positive memory recall will reduce negative affective state, reduce explore-exploit biases and normalize the associated brain activity. The investigators propose a randomized double-blind, sham-controlled trial of positive autobiographical memory recall with 80 adults (n=40 per arm) with methamphetamine use disorder (MUD) currently involved in abstinence only treatment centers.

NCT ID: NCT06372288 Recruiting - Clinical trials for Methamphetamine Abuse

Theta Burst TMS for Treatment of Methamphetamine Use Disorder

Start date: December 20, 2023
Phase: N/A
Study type: Interventional

This study is using Transcranial Magnetic Stimulation (TMS) to determine if interventional psychiatry treatment can help with the treatment of Methamphetamine Use Disorder. Individuals with Methamphetamine Use Disorder will receive 5 consecutive TMS treatment sessions based off of randomization. Participants will be randomized to one of two groups. TMS treatment arm or sham-TMS arm.

NCT ID: NCT06316973 Recruiting - Clinical trials for Substance Use Disorders

A Clinical Study to Evaluate the Safety of CS-1103 in Healthy Participants

Start date: February 7, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this Phase 1a study is to evaluate safety, tolerability, and pharmacokinetics (PK) of single, ascending doses of CS-1103, administered by intravenous (IV) infusion in healthy participants.

NCT ID: NCT06292156 Recruiting - Clinical trials for Methamphetamine Abuse

tACS Treatment for Cognitive Impairments in Methamphetamine Addicts

Start date: February 20, 2023
Phase: N/A
Study type: Interventional

1. To evaluate the cognitive function of methamphetamine Patients. 2. Investigate the pathological mechanism of methamphetamine patients from the aspects of EEG and biology; 3. The investigators investigated the effects of transcranial alternating current stimulation (tACS) on cognitive impairments in methamphetamine patients

NCT ID: NCT06233799 Not yet recruiting - Clinical trials for Methamphetamine Abuse

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

Start date: May 1, 2024
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the efficacy of extended release naltrexone plus bupropion XL (XR-NTX/BUP-XL) compared to matched injectable and oral placebo (iPLB/oPLB) in reducing methamphetamine (MA) use in individuals with moderate or severe methamphetamine use disorder (MUD) seeking to stop or reduce MA use.

NCT ID: NCT05971043 Not yet recruiting - Clinical trials for Methamphetamine Abuse

Skin Disease in Methamphetamine Abuse

Start date: August 3, 2023
Phase:
Study type: Observational

1. To detect the skin diseases in patients using methamphetamine

NCT ID: NCT05916989 Completed - HIV Infections Clinical Trials

Stimulant Use and Methylation in HIV

Start date: September 30, 2018
Phase:
Study type: Observational

This study will leverage extracted leukocyte DNA specimens from a completed NIH-funded project to examine the efficacy of a behavioral intervention model that reduced stimulant use on DNA methylation over 6 months.

NCT ID: NCT05854667 Recruiting - Addiction Clinical Trials

Clinical Trial of High Dose Lisdexamfetamine and Contingency Management in MA Users

Start date: December 5, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to learn if administering a high dose stimulant with Contingency Management reduces days of use in adults who use methamphetamine better than the usual treatment provided by the clinic. The main questions the trial aims to answer are: Is a high dose stimulant better than a placebo and usual treatment at helping reduce the number of days they use methamphetamine? Is a high dose stimulant with contingency management better than placebo and usual treatment at helping people reduce the number of days they use methamphetamine? Participants will be placed randomly into one of four groups: 1. Usual treatment and placebo 2. Usual treatment, placebo and contingency management 3. Usual treatment and high dose stimulant 4. Usual treatment, high dose stimulant and contingency management Participation includes the following: 1. Participants will receive medication or placebo weekly for 15 weeks. 2. Participants will attend the clinic for weekly treatment 3. Participants will attend the clinic once every 2 weeks for study visits. Each visit will take about an hour to complete. At these visits, participants will be asked to provide a urine sample and complete questionnaires.

NCT ID: NCT05784467 Not yet recruiting - Hiv Clinical Trials

Methamphetamine, PrEP, and Intersectional Stigma Study

eMPrISe
Start date: June 1, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trail is to test the developed eMPrISe study in HIV-negative, adult, Latino men who have sex with men (MSM) who use non-injection substances. The main questions it aims to answer are: - Can participation in the developed eMPrISe study reduce methamphetamine ('meth') use risk? - Can participation in the developed eMPrISe study improve preexposure prophylaxis (PrEP) cascade progression? Participants will participate in 12 weekly modules that: (1) build critical thinking skills, (2) identify and discuss the link between oppression and harmful behaviors, (3) take action, (4) voice and validate feelings and experiences, and (5) share knowledge and resources.

NCT ID: NCT05700994 Recruiting - Clinical trials for Methamphetamine Abuse

Peer Engagement in Methamphetamine Harm-Reduction With Contingency Management (PEER-CM)

Start date: November 13, 2023
Phase: N/A
Study type: Interventional

The main goal of this study is to tests the effect of incentivizing achievement of self-identified, personal harm reduction goals (Contingency management or CM) compared with standard of care (peer harm reduction service with incentives for peer visits) to increase the reach and effectiveness of methamphetamine (MA) harm reduction services.